Swanbio Therapeutics, Inc.
Clinical trials sponsored by Swanbio Therapeutics, Inc., explained in plain language.
-
Gene therapy trial for rare nerve disease halted early
Disease control TerminatedThis study tested a one-time gene therapy (SBT101) given into the spinal fluid to treat adrenomyeloneuropathy (AMN), a rare inherited nerve disease that causes walking problems. The trial enrolled 8 adults aged 18-65 and was terminated early. The goal was to check safety and whet…
Phase: PHASE1, PHASE2 • Sponsor: SwanBio Therapeutics, Inc. • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New study aims to map rare nerve disease progression
Knowledge-focused TerminatedThis study looked at how walking ability and quality of life change over time in adults with a rare inherited nerve disease called AMN (a form of spastic paraplegia). Researchers followed 65 men aged 18 and older who had spinal cord symptoms. The goal was to better understand the…
Sponsor: SwanBio Therapeutics, Inc. • Aim: Knowledge-focused
Last updated May 20, 2026 11:56 UTC